VKTX01: A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients. IMAGINE (Interleukin 6 Blockade Modifying Antibody-Mediated Graft INjury a